A.O. Ospedale Papa Giovanni XXIII
Quick facts
Marketed products
- fludarabine, cyclophosphamide, doxorubicin, rituximab
- Rilpivirine + darunavir/cobicistat · Infectious Disease (HIV/AIDS)
This combination inhibits HIV reverse transcriptase and protease to block viral replication, with cobicistat enhancing darunavir levels.
Phase 3 pipeline
- stable HAART · Infectious Diseases
Stable HAART refers to a long-term antiretroviral therapy regimen that maintains viral suppression in HIV-1 infected patients.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- A.O. Ospedale Papa Giovanni XXIII portfolio CI brief
- A.O. Ospedale Papa Giovanni XXIII pipeline updates RSS
Frequently asked questions about A.O. Ospedale Papa Giovanni XXIII
What are A.O. Ospedale Papa Giovanni XXIII's marketed drugs?
Top marketed products include fludarabine, cyclophosphamide, doxorubicin, rituximab, Rilpivirine + darunavir/cobicistat.
What is A.O. Ospedale Papa Giovanni XXIII's pipeline?
A.O. Ospedale Papa Giovanni XXIII has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include stable HAART.
Related
- fludarabine, cyclophosphamide, doxorubicin, rituximab
- Rilpivirine + darunavir/cobicistat · Infectious Disease (HIV/AIDS)
- Sector hub: All tracked pharma companies